Vitiligo

Immunology·MeSH: Vitiligo

21 drugs in development·12 companies·9 clinical trials

Drug Pipeline by Phase

Approved(3)

Phase 3(3)

Drug	Company
povorcitinib	Incyte Corp. (INCY)
tev-53408	Teva Pharmaceutical Industries Limited (TEVA)
vehicle	Incyte Corp. (INCY)

Phase 2(13)

Drug	Company
eb06	Edesa Biotech, Inc. (EDSA)
fb-102	Forte Biosciences, Inc. (FBRX)
fb102	Forte Biosciences, Inc. (FBRX)
gia632	Novartis AG (NVS)
GIA632	Novartis AG (NVS)
ly4005130	ELI LILLY & Co (LLY)
melanotan ii	IO Biotech, Inc. (IOBT)
repibresib	VYNE Therapeutics Inc. (VYNE)
SHR0302 Base Gel	Crinetics Pharmaceuticals, Inc. (CRNX)
SHR0302 Tablets	Crinetics Pharmaceuticals, Inc. (CRNX)
vehicle gel	VYNE Therapeutics Inc. (VYNE)
vyn201	VYNE Therapeutics Inc. (VYNE)
vyn201 gel	VYNE Therapeutics Inc. (VYNE)

Phase 1(2)

Drug	Company
ARQ-252	Arcutis Biotherapeutics, Inc. (ARQT)
ARQ-255	Arcutis Biotherapeutics, Inc. (ARQT)

BioSniper tracks 21 drugs in development for Vitiligo across 12 companies.

There are 9 clinical trials targeting Vitiligo tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.